Botulinum toxins block acetylcholine release from synaptic nerve terminals and thus
interfere with neural signaling. Botulinum toxin type A (BTA) is one of several such
endotoxins that prevents fusion of acetylcholine vesicles with the terminal membrane,
resulting in impairment of cholinergic-based neural transmission. It has been tested
extensively for clinical use and is indicated for a variety of noncardiac conditions,
with an excellent safety record.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Short-term autonomic denervation of the atria using botulinum toxin.Korean Circ J. 2010; 40: 387-390
- Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation.Circ Arrhythm Electrophysiol. 2011; 4: 560-565
- Temporary suppression of cardiac ganglionated plexi leads to long-term suppression of atrial fibrillation: evidence of early autonomic intervention to break the vicious cycle of “AF begets AF.”.J Am Heart Assoc. 2016; 5e003309
- Botulinum toxin injection in epicardial fat pads can prevent recurrences of atrial fibrillation after cardiac surgery.J Am Coll Cardiol. 2014; 64: 628-629
- Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: one year follow up of a randomized pilot study.Circ Arrhythm Electrophysiol. 2015; 8: 1334-1341
- Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: three-year follow-up of a randomized study.Heart Rhythm. 2019; 16: 172-177
- Design and rationale of a phase 2 study of neurOtoxin (Botulinum Toxin Type A) for the preVention of post-operative atrial fibrillation—the NOVA study.Am Heart J. 2022; 245: 51-59
- Ultrasound-guided injection of botulinum toxin type A blocks cardiac sympathetic ganglion to improve cardiac remodeling in a large animal model of chronic myocardial infarction.Heart Rhythm. 2022; 19: 2095-2104
Article info
Publication history
Published online: September 05, 2022
Footnotes
Funding Sources: Dr Steinberg had received research funding from the NIH (R34HL153579).
Disclosures: Dr Steinberg had received research funding from Medtronic, AliveCor, National Cardiac, AbbVie, and AtriCure. Dr Romanov has no conflicts of interest to disclose.
Identification
Copyright
© 2022 Heart Rhythm Society. All rights reserved.
